Federal grants to Cytoagents Inc
Cytoagents Inc in Pittsburgh, Pennsylvania received $6.1 million in federal grants from fiscal 2021 to 2025, across 4 awards. Its largest program was Cancer Treatment Research, with $3.3 million. In fiscal 2025 it was awarded $2.3 million.
From USAspending.gov award records, updated October 31, 2026.
- Grants, FY 2021 to 2025$6.1 million
- Awards4
- Awarded in FY 2025$2.3 million
- Largest award$2.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 2 | $1.8 million |
| FY 2022 | 1 | $1.0 million |
| FY 2023 | 0 | $0 |
| FY 2024 | 1 | $994,858 |
| FY 2025 | 2 | $2.3 million |
Programs that fund Cytoagents Inc
| Program | Awards | Amount |
|---|---|---|
| Cancer Treatment Research | 2 | $3.3 million |
| Allergy and Infectious Diseases Research | 2 | $2.8 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 4 | $6.1 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Preclinical development of an immunomodulatory agent capable of mitigating SARS-COV-2 virus related hypercytokinemia - abstract cytoagents is developing GP1681 (BERAPROST-314D) to regulate the uncontrolled inflammatory response that can result from viral infections. This inflammatory response is ass | Allergy and Infectious Diseases Research | March 5, 2021 | $2.0 million |
| CTO1681 to prevent and mitigate cytokine release syndrome in car t-cell recipients - abstract cytoagents is developing CTO1681 for the prevention and treatment of cytokine release syndrome (CRS) associated with chimeric antigen receptor (CAR) t-cell therapy. Car t-cell therapy has emerged as a very | Cancer Treatment Research | September 20, 2024 | $2.0 million |
| CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving car t-cell therapy - abstract cytoagents is developing CTO1681 for the prevention and treatment of cytokine release syndrome (CRS) associated with chimeric antigen receptor (CAR) t-cell therapy. Car t-ce | Cancer Treatment Research | September 19, 2025 | $1.3 million |
| Preclinical development of an immunomodulatory agent capable of mitigating influenza related hypercytokinemia | Allergy and Infectious Diseases Research | April 15, 2021 | $813,513 |
Questions people ask
How much federal grant money does Cytoagents Inc get?
$6.1 million in 4 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Cytoagents Inc the most?
The Department of Health and Human Services, with $6.1 million in 4 awards.
What is Cytoagents Inc's largest federal grant?
$2.0 million under Allergy and Infectious Diseases Research, with its first action in the period on March 5, 2021. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Cytoagents Inc?
Its largest are Cancer Treatment Research and Allergy and Infectious Diseases Research.
Other grant recipients in Pittsburgh
- University of Pittsburgh - of the Commonwealth System of Higher Education
- Port Authority of Allegheny County Inc
- Carnegie-Mellon University
- Housing Authority of the City of Pittsburgh
- County of Allegheny
- Allegheny County Airport Authority
- Kraft Heinz Foods Company
- Magee-Womens Research Institute and Foundation
Largest federal grant recipients in Pennsylvania · Federal grants in Pennsylvania